Suppr超能文献

正常和肝硬化人类肝脏中的己糖激酶同工酶:肝硬化中葡萄糖激酶的抑制

Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.

作者信息

Lowes W, Walker M, Alberti K G, Agius L

机构信息

Department of Medicine, Human Diabetes and Metabolism Research Centre, The University of Newcastle upon Tyne, UK.

出版信息

Biochim Biophys Acta. 1998 Jan 8;1379(1):134-42. doi: 10.1016/s0304-4165(97)00092-5.

Abstract

The activities of hexokinase isoenzymes I-IV (EC 2.7.1.1) and of N-acetylglucosamine kinase (EC 2.7.1.59) were determined in normal human liver and in alcoholic liver disease and primary biliary cirrhosis after FPLC fractionation of high-speed supernatants on Mono-Q with a linear NaCl gradient. In control human liver the hexokinase activities were: I, 3.6; II, 0.7; III, 3.5, IV, 4.8 (mUnits/mg supernatant protein). The activity of N-acetylglucosamine kinase was 8 mU/mg of protein. In alcoholic liver disease and primary biliary cirrhosis, the activity of hexokinase IV (glucokinase) was suppressed to less than 10% of control activity and the activity of hexokinase I was increased 3-fold. The activity of hexokinase II was increased approximately 7-fold in alcoholic liver disease. The activities of hexokinase III and N-acetylglucosamine kinase were unchanged in cirrhosis. Hexokinase III showed 50% substrate inhibition at 100 mM glucose as compared with 0.5mM glucose. The high activity of hexokinase III in human liver (approximately 50% of the low-Km activity and 70% of glucokinase activity) results in a significant underestimation of glucokinase activity as determined by the conventional spectrometric assay while the activity of N-acetylglucosamine kinase may contribute to an overestimation of glucokinase activity in the radiochemical assay. Furthermore glucokinase is dramatically suppressed in liver disease, which although partly compensated for by the increase in hexokinase I (and II), accounts in part for the well-known glucose intolerance of liver cirrhosis.

摘要

在对高速上清液进行快速蛋白质液相色谱(FPLC)分级分离后,利用线性氯化钠梯度在Mono-Q柱上测定了正常人肝脏、酒精性肝病和原发性胆汁性肝硬化中己糖激酶同工酶I-IV(EC 2.7.1.1)和N-乙酰葡糖胺激酶(EC 2.7.1.59)的活性。在对照人肝脏中,己糖激酶的活性分别为:I型3.6、II型0.7、III型3.5、IV型4.8(毫单位/毫克上清液蛋白)。N-乙酰葡糖胺激酶的活性为8毫单位/毫克蛋白。在酒精性肝病和原发性胆汁性肝硬化中,己糖激酶IV(葡萄糖激酶)的活性被抑制至对照活性的10%以下,而己糖激酶I的活性增加了3倍。在酒精性肝病中,己糖激酶II的活性增加了约7倍。在肝硬化中,己糖激酶III和N-乙酰葡糖胺激酶的活性未发生变化。与0.5毫摩尔葡萄糖相比,己糖激酶III在100毫摩尔葡萄糖时表现出50%的底物抑制作用。人肝脏中己糖激酶III的高活性(约占低Km活性的50%和葡萄糖激酶活性的70%)导致用传统光谱法测定的葡萄糖激酶活性被显著低估,而在放射化学测定中,N-乙酰葡糖胺激酶的活性可能导致葡萄糖激酶活性被高估。此外,葡萄糖激酶在肝病中被显著抑制,尽管部分被己糖激酶I(和II)的增加所补偿,但这部分解释了肝硬化中众所周知的葡萄糖不耐受现象。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验